☞ On deadline? For media inquiries CLICK HERE.
October 3: APC CompoundED UpDATE: A Regional Gathering, Renton, WA
October 14-17: ISTX24: PCCA International Seminar, Houston
October 22: APC webinar with Pharmacists Mutual: Coverage, Claims, and Compounding: What You Need to Know About Your Liability Insurance
October 29: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (1 of 2)
November 15-17: Personalized Medicine Certification Course 1: Endocrinology in St. Pete Beach, Fla.
December 4: PCAC meeting on adding several bulk drug substances to the 503A Bulks List (2 of 2)
December 13: APC Board of Directors Meeting, Las Vegas
December 13-15: A4M Longevity Fest, Las Vegas
Since the FDA announced that tirzepatide is (for now) out of shortage, APC's Scott Brunner has been all over the news offering our perspective.
Baseless but time-consuming lawsuit threats make compounders shy.
The piece spends a lot of time considering misconceptions about compounded GLP-1s, but it least it included a little straight info from Scott.
Scott tells Medscape that actually helping patients with vial-based tirzepatide is a welcome change for Lilly.
"It is absolutely intentional policy on the part of FDA."
Don't expect brand-name GLP1s to be available long-term, he says
The California Board of Pharmacy looked to ban glutathione, but the pushback was hard.
The Washington Post's story "Eli Lilly ramps up its fight against imitation weight-loss drugs" contains a short quote from CEO Scott Brunner.
In its article on Lilly's introduction of DTC discounted vials of Zepbound, IHP included a great quote from CEO Scott Brunner.
You’ve probably seen the news that Eli Lilly will begin selling Zepbound in vials by mail. What you may have missed is that the CBS News story quoted APC CEO Scott Brunner.
Inside Health Policy used APC for information in its piece “Uncertainty Looms Over Bulk Production Of Personalized GLP-1 Drugs.”
Our comment to FDA about its use of the Pharmacy Compounding Advisory Committee (PCAC) was covered in detail by Inside Health Policy.